CARM: Carisma Therapeutics Inc Price to Sales
Carisma Therapeutics (CARM) revenue valuation demonstrates volatility amid a fierce battle for leadership in oncotherapy, a sector dominated by resource-rich behemoths. Meanwhile, 0.60 represents the latest metric reading, highlighting the dependence of Carisma Therapeutics (CARM) on external contract manufacturing organizations. Stability is provided by the unique CAR-M platform, which creates a closed patent perimeter and ties clinics to long-term treatment protocols.
Analytical breakdowns for Carisma Tx (CARM)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Carisma Therapeutics|CARM - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Carisma Therapeutics Inc|CARM - Company Debts|Debts to Net Assets Carisma Therapeutics|CARM - Company Long-Term Debt|Company Current Liabilities Carisma Therapeutics|Quick Ratio carismatx.com
- business earnings and investment ratios data:
CARM - Net Income|Expected Net Income Carisma Therapeutics|CARM - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Carisma Therapeutics Inc.|CARM - PEG Multiple|Business Value to Operating Income Before Depreciation CARM|CARM - Operating profit EBITDA|Net earnings per one share for the last twelve months Carisma Therapeutics|CARM - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months carismatx.com|CARM - Earnings growth in current year|Earnings growth forecast for next year Carisma Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:CARM, Carisma Therapeutics
Carisma Therapeutics (CARM) utilizes external CDMO facilities to scale the production of immunotherapies, thereby minimizing capital expenditures. The company's current P/S ratio compares total market capitalization to generated revenue, revealing the actual value of each dollar of sales. This chart's price action allows for the separation of market euphoria from fundamental business performance metrics. Extreme indicator values signal either a critical overheating of the asset or a systemic decline in demand.
Competitors of Carisma Therapeutics
argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|P/S Multiple enlivex.com ENLV|QTTB: Market Cap to Revenue|GOVX - P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Revenue Ratio|IBIO - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple
